Koninklijke Philips posted robust fourth-quarter results, with net income swinging to €397 million from a €333 million loss in 2024. The Dutch health-tech firm saw 7% comparable sales growth across its medical systems and connected-care divisions, while adjusted EBITA margin expanded 160 basis points to 15.10%.

Free cash flow reached €1.20 billion despite ongoing costs from the Respironics sleep-device recall. All three business units contributed to growth, with the personal health segment delivering 14% comparable sales gains. Operational income more than doubled to €540 million as restructuring charges fell 37% year-over-year.

Full-year sales edged up 2% to €17.83 billion despite tariff pressures, with China driving 15% growth in developing markets. CEO Roy Jakobs pointed to €2.20 billion in annual adjusted EBITA as evidence of improved execution. The company maintained its 2026 guidance for 3-4.5% sales growth and proposed an €0.85 per share dividend.